1
Sep
2022

FDA Clears Bivalent Vaccines, Novo Buys Forma, & Novartis R&D Chief Moves On

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

J&J Doubles Down on Neuro, Lilly Acquires Scorpion, Umoja Pulls in $100M
Novo, Variant Benefit Sharing Win, Verdiva Joins Obesity Fray & Maze Eyes IPO
Vertex Pain Drug Fails, Puretech Delivers for IPF, Merck Dumps TIGIT, LAG3 Antibodies
ASH Recap, Dimension Captures $500M, & AbbVie’s New Parkinson’s Drug